<DOC>
	<DOCNO>NCT00267930</DOCNO>
	<brief_summary>This study design evaluate safety , tolerability preliminary efficacy vernakalant ( oral ) subject sustain atrial fibrillation great 72 hour less 6 month duration</brief_summary>
	<brief_title>Study RSD1235-SR Prevention Atrial Fibrillation/Atrial Flutter Recurrence</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Atrial Flutter</mesh_term>
	<criteria>Inclusion Criteria ( partial list ) : Subjects must sustain , symptomatic atrial fibrillation great 72 hour less 6 month duration Subjects must adequate anticoagulant therapy Exclusion Criteria ( partial list ) : Subjects may Class III Class IV congestive heart failure Subjects may uncorrected electrolyte imbalance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>AFib</keyword>
	<keyword>AF</keyword>
</DOC>